Meal Delivery and Exercise

December 15, 2023 updated by: Jessica Lee, The University of Texas Health Science Center, Houston

A Meal Delivery and Exercise Intervention to Increase Resilience in Homebound Older Adults

The purpose of this study is to evaluate the effects of a home-based exercise program administered through Meals on wheels (MOW) on gait speed and frailty status and to assess the association between novel serum biomarkers (70 kilodalton heat shock proteins (HSP70),Macrophage Inflammatory Proteins(MIP1b), soluble IL-6 receptor alpha-chain (sIL-6R)) and established but non-specific frailty biomarkers (Interleukin 6 (IL-6), C-reactive protein (CRP), Tumor necrosis factor (TNF-α)) in frail and prefrail homebound older adults before and after the exercise intervention.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • homebound (normally unable to leave the home unassisted)
  • frail or prefrail by The Fried Frailty Phenotype (FFP)
  • medically stable

Exclusion Criteria:

  • robust by FFP
  • have Mini-Cog score <3 and/or are unable to follow instructions
  • have a pre-diagnosed terminal illness
  • unable to ambulate
  • unable to use their upper extremities, and/or are already participating in physician-prescribed physical therapy or occupational therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Meals plus exercise
Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
Experimental: Meals only
Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in gait speed
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
this is the time one takes to walk a specified distance on level surfaces over a short distance and is measured in meters/second
4 weeks,8 weeks,12 weeks from baseline
Change in total FFP score as assessed by the Fried Frailty Phenotype (FFP) screening test
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
Score from 0(not frail),1-2(pre frail) and 3-5(frail)
4 weeks,8 weeks,12 weeks from baseline
Change in measure of HSP70 (ng/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Change in Measure of MIP-1β (pg/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Change in Measure of sIL-6R (pg/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in overall frailty status as assessed by the Fried Frailty Phenotype (FFP) screening test
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
The FFP defines frailty as having 3 or more characteristics of unintentional weight loss, fatigue, decreased physical activity, weakness, and slowness.Those who have 1 or 2 characteristics are considered pre frail, while those who have no characteristics are robust.
4 weeks,8 weeks,12 weeks from baseline
Change in grip strength
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
Grip strength is a measure of muscular strength or the maximum force/tension generated by one's forearm muscles .This is measured by using a dynamometer which will be squeezed by the participant 3 times in each hand.The force is measured in kilograms.
4 weeks,8 weeks,12 weeks from baseline
Change in daily average steps from the activity tracker
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Number of patients that required emergency room visits
Time Frame: 6 months post baseline visit
6 months post baseline visit
Number of patients that required hospitalization
Time Frame: 6 months post baseline visit
6 months post baseline visit
Change in activities of daily living as measured by the Katz Index of Independence in Activities of Daily Living
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
This consists of 6 questions and each is scored form 0(patient is very dependent)-6(patient is independent)
4 weeks,8 weeks,12 weeks from baseline
Change in instrumental activities of daily living as measured by the LAWTON - BRODY INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (I.A.D.L.)
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
This consists of 8 questions and each has a summary score range from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men to avoid potential gender bias.
4 weeks,8 weeks,12 weeks from baseline
Change in loneliness as assessed by the UCLA Loneliness Scale (ULS)
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
This questionnaire consists of 20 questions and each is answered from 1(never)-4(always) for a total score ranging form 20-80
4 weeks,8 weeks,12 weeks from baseline
Social network as assessed by the LUBBEN SOCIAL NETWORK SCALE - 18 (LSNS-18)
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
LSNS-R total score is an equally weighted sum of twelve items. Scores range from 0 to 90, a higher number indicating a better outcome
4 weeks,8 weeks,12 weeks from baseline
change in measure of IL-6 (pg/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Change in measures of CRP (ng/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Change in measures of TNF-α (pg/mL) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
Change in measures of microbiome (fecal sample) expression
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in IL-6 (pg/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in CRP (ng/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in TNF-α (pg/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in HSP70 (ng/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in MIP-1β (pg/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in sIL-6R (pg/mL) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline
change in microbiome (fecal sample) as measured by the frailty status
Time Frame: 4 weeks,8 weeks,12 weeks from baseline
4 weeks,8 weeks,12 weeks from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jessica Lee, MD,MS, The University of Texas Health Science Center, Houston

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 19, 2021

Primary Completion (Estimated)

February 28, 2026

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

May 25, 2021

First Submitted That Met QC Criteria

May 25, 2021

First Posted (Actual)

May 28, 2021

Study Record Updates

Last Update Posted (Estimated)

December 21, 2023

Last Update Submitted That Met QC Criteria

December 15, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HSC-MS-21-0125
  • 1K23AG072042-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on Meals plus exercise

3
Subscribe